Company / Current Assets
Esperion Therapeutics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$462.6M
FY2025
5-year range
$201.1M / $462.6M
FY2021-FY2025
Trend
+36.9%
vs FY2024
Sector context
#123 of 213
Health Care
What the data says
At $463M, Esperion Therapeutics, Inc.'s current assets ranks #123 of 213 in the Health Care sector. Current Assets has fluctuated over the past 10 years, ranging from $143M in FY2018 to $463M in FY2025.
Based on SEC 10-K filings.
$463M in FY2025 with a 5-year CAGR of +6.0%.
Improved from $201M to $463M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +23.3%
- 5-Year CAGR
- +6.0%
- 10-Year CAGR
- -
Sector benchmark
#123 of 213 in Health CareTop 58% of 213This company $462.6M Sector average $2.5B
▼
-81.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.0%, indicating consistent growth.
- In FY2025, current assets increased 36.9% year-over-year.
- Ranks #123 out of 213 companies in the Health Care sector.
- Lowest current assets in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $462.6M | +36.9% |
| FY2024 | $338.0M | +68.1% |
| FY2023 | $201.1M | -18.5% |
| FY2022 | $246.7M | -25.0% |
| FY2021 | $329.0M | -4.9% |
| FY2020 | $345.9M | +63.4% |
| FY2019 | $211.7M | +48.4% |
| FY2018 | $142.6M | -30.1% |
| FY2017 | $203.9M | -4.5% |
| FY2016 | $213.6M | -0.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026